- Home
- NRIX vs TPB Comparison
NRIX vs TPB Comparison
Compare NRIX & TPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- TPB
- Stock Information
- Founded
- NRIX 2009
- TPB 1988
- Country
- NRIX United States
- TPB United States
- Employees
- NRIX N/A
- TPB N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- TPB Tobacco
- Sector
- NRIX Health Care
- TPB Consumer Discretionary
- Exchange
- NRIX Nasdaq
- TPB Nasdaq
- Market Cap
- NRIX 1.1B
- TPB 1.2B
- IPO Year
- NRIX 2020
- TPB 2016
- Fundamental
- Price
- NRIX $12.06
- TPB $74.33
- Analyst Decision
- NRIX Strong Buy
- TPB Strong Buy
- Analyst Count
- NRIX 17
- TPB 4
- Target Price
- NRIX $30.71
- TPB $73.75
- AVG Volume (30 Days)
- NRIX 739.8K
- TPB 246.5K
- Earning Date
- NRIX 07-10-2025
- TPB 05-07-2025
- Dividend Yield
- NRIX N/A
- TPB 0.40%
- EPS Growth
- NRIX N/A
- TPB N/A
- EPS
- NRIX N/A
- TPB N/A
- Revenue
- NRIX $56,417,000.00
- TPB $384,032,000.00
- Revenue This Year
- NRIX $15.43
- TPB $21.66
- Revenue Next Year
- NRIX N/A
- TPB $9.08
- P/E Ratio
- NRIX N/A
- TPB $31.53
- Revenue Growth
- NRIX N/A
- TPB 24.54
- 52 Week Low
- NRIX $8.18
- TPB $30.62
- 52 Week High
- NRIX $29.56
- TPB $81.05
- Technical
- Relative Strength Index (RSI)
- NRIX 66.26
- TPB 63.09
- Support Level
- NRIX $9.67
- TPB $70.33
- Resistance Level
- NRIX $10.79
- TPB $75.26
- Average True Range (ATR)
- NRIX 0.60
- TPB 1.83
- MACD
- NRIX 0.27
- TPB -0.29
- Stochastic Oscillator
- NRIX 84.13
- TPB 83.85
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About TPB Turning Point Brands Inc.
Turning Point Brands Inc operates as manufacturer, marketer, provider of consumer products that include Other Tobacco Products (OTP) in the U.S. The company offers a wide variety across the OTP spectrum including moist snuff tobacco (MST), loose-leaf chewing tobacco, premium cigarette papers, make- your-own (MYO) cigar wraps, cigars, liquid vapor products, and tobacco vaporizer products. It operates in three segments namely Zig-Zag products; Stoker's products and NewGen products. The company generates maximum revenue from the Zig-Zag products segment.